Sort
261,768 grants matching “gene therapy”
The Cancer Target Discovery and Development Network at UCSF
$1,000,618Michael T McManus · University Of California, San Francisco · U01 · FY2019 · CA
Live microbial therapeutics: an enhanced treatment paradigm for classical homocystinuria
$1,000,496Joseph Moeller Schinaman · Petri Bio Llc · R44 · FY2024 · HD
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed
$1,000,449Maria Constance Athanasiou · Marpam Pharma, Llc · R42 · FY2024 · AI
Safety of Estrogen in Lupus Erythematosus
$1,000,306Hospital For Joint Diseases Ortho Inst · U01 · FY2001 · AR
Mouse Genetics
$1,000,292Yasuhide Furuta · Sloan-Kettering Inst Can Research · P30 · FY2019 · CA
TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
$1,000,260Wanjun Chen · Dental & Craniofacial Research · Z01 · FY2007 · DE
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
$1,000,114Priscilla Y. Hsue · University Of California, San Francisco · R01 · FY2011 · HL
Very Low Frequency EPR Imaging in Vivo Phisiology P41 EB02034
$1,000,099Howard J Halpern · University Of Chicago · P41 · FY2012 · EB
Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform
$1,000,088Lyndsey Linke · Sivec Biotechnologies, Llc · R44 · FY2022 · AI
Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy
$1,000,002Hunter Nicole Bomba · Cancer Targeted Technology, Llc · R44 · FY2021 · CA
LIVER PATHOBIOLOGY AND GENE THERAPY RESEARCH CORE CENTER
$1,000,001Yeshiva University · P30 · FY2003 · DK
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model
$1,000,000Richard P Junghans · It Bio, Llc · R44 · FY2022 · AI
A Once-Weekly Oral Tacrolimus-Prednisone Fixed-Dose Combination Therapy for Post-Transplant Maintenance Immunosuppressive Therapy
$1,000,000Stephen Zale · Lyndra Therapeutics, Inc. · R44 · FY2020 · AI
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
$1,000,000Saumya Das · Massachusetts General Hospital · UH3 · FY2016 · TR
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
$1,000,000Rene Gonzalez · Trampoline Pharma, Inc. · R44 · FY2022 · CA
HPMI: Host Pathogen Mapping Initiative
$1,000,000Nevan J Krogan · University Of California, San Francisco · U19 · FY2021 · AI
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
$1,000,000Richard C Duke · Trampoline Pharma, Inc. · R44 · FY2023 · CA
Creatine Safety and Efficacy in HD: Coordination and Statistical Center
$1,000,000Giovanni Schifitto · University Of Rochester · U01 · FY2014 · AT
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders
$1,000,000Henryk Dudek · Dicerna Pharmaceuticals, Inc. · U44 · FY2019 · AA
RAISE: A Phase Separation Model for Transcriptional Control in Mammals
$1,000,000Arup K Chakraborty · Massachusetts Institute Of Technology · · FY2017 · MPS
A parallelized computational microscope platform for high-throughput live imaging of patient-derived organoids
$1,000,000Mark Harfouche · Ramona Optics, Inc. · R44 · FY2025 · CA
University of New Mexico Cancer Center Support Grant
$1,000,000Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2020 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments
$1,000,000Michael H Cardone · Eutropics Pharmaceuticals, Inc. · R44 · FY2019 · CA
Guide RNA manufacturing capabilities for platform in vivo base editing therapies for metabolic liver diseases
$1,000,000William H. Peranteau · Children'S Hosp Of Philadelphia · U19 · FY2025 · NS